Lenacapavir (GS-6207) is a novel, first-in-class, long-acting and highly potent HIV-1 capsid inhibitor approved in EU on August 22, 2022 to treat HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis. It exhibits anti-HIV activity with an EC50 of 100 pM in MT-4 cells. Lenacapavir exhibits a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).

纯度：≥98%

CAS：2189684-44-2